Navigation Links
Growth Hormone Boost May Not Slow Alzheimer's
Date:11/19/2008

A promising approach in mice disappoints in human trial

WEDNESDAY, Nov. 19 (HealthDay News) -- A compound that boosts growth hormone levels in Alzheimer's patients may not slow the disease, new research suggests.

The study, funded by drug giant Merck, was spurred by promising animal research that had suggested that the compound, called MK-677, might help curb Alzheimer's effect on the brain.

However, "the study suggests that targeting this hormone system may not be an effective approach at slowing the rate of Alzheimer's disease progression," said study author Dr. J.J. Sevigny, associate director of clinical neuroscience at Merck Research Laboratories in North Wales, Pa. His team reported its finding in the Nov. 18 issue of Neurology.

"In a similar vein, the study challenges a commonly held theory that hormones may attack beta-amyloid plaque in the brain," Sevigny added. "That was the premise of this research: that by giving this medication we'd be able to influence the beta-amyloid in the brain. And we didn't receive this result in this study."

Based on the findings, Merck has now stopped investigating MK-677 for use against Alzheimer's.

The study comes on the heels of another report on the drug, published earlier this month in the Annals of Internal Medicine.

In that study, researchers at the University of Virginia found the use of MK-677 spurred an increase in muscle mass in older recipients. It also improved their fat distribution and boosted appetite as it restored the body's production of growth hormone to youthful levels. The intervention did not demonstrate any specific benefit with respect to boosting overall muscle strength or activity function, however.

In the new study, conducted between 2003 and 2005, Sevigny's team tracked the cognitive health of 416 U.S. patients with mild to moderate Alzheimer's disease, aged 50 and above.

During the study, half the patients received 25-milligram tablets of MK-677, while the other half consumed a placebo.

The researchers found that MK-677 was well-tolerated and produced a desirable 60 percent-plus increase in the pituitary gland's production of insulin-like growth factor-1 (IGF-1) within just six weeks. This boost increased to nearly 73 percent by the end of one year.

Prior work with mice has suggested that a rise in IGF-1 might trigger a drop in levels of beta-amyloid brain plaque, long associated with Alzheimer's disease. So the hope was that plaques -- and associated symptoms -- might decline in Alzheimer's patients as IGF-1 levels rose.

However, after rating patient mental health according to a standard "clinical dementia" scale the authors found that the MK-677-mediated boost in IGF-1 did not translate into any slowdown in Alzheimer's disease progression.

Although the study has offered meaningful opportunities to learn a "tremendous amount about the possible causes of Alzheimer's disease", Sevigny said his team at Merck will now be "moving on to other options" for therapeutic research.

Maria C. Caprillo is director of medical and scientific relations at the national office of the Alzheimer's Association in Chicago. She said that growth hormone therapy's failure to stem disease progression might be due to the fact that plaque build-up can begin as much as 10 years before an Alzheimer's diagnosis.

"So, even though animal work has suggested that growth hormone could be neuroprotective, it's not too surprising that it didn't have an effect, given that when you're looking at mild-to-moderate Alzheimer patients it simply may be a little too late," she said.

"Regardless of the reason -- and there are still a lot of unknowns -- the bottom line is that this compound did not produce positive results, and did not improve cognition or the ability to carry out the activities of daily living," Caprillo noted. "Which is, of course, disappointing -- that another line of potential research may not prove fruitful for people who so desperately need something today."

More information

For more on the role of plaque in Alzheimer's, visit the Alzheimer's Association.



SOURCES: J.J. (Jeffrey) Sevigny, M.D, associate director, clinical neuro-science, Merck Research Laboratories, North Wales, Pa.; Maria C. Carillo, Ph.D., director, medical & scientific relations, Alzheimer's Association, National Office, Chicago; Nov. 18, 2008, Neurology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. High pollution linked to poor lung function growth in children in Mexico City
2. Researchers develop long-lasting growth hormone
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
5. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
6. AWT Management Announce Aggressive Growth and Acquisition Strategy
7. Cynosure to Present at the Maxim Group Growth Conference
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
10. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Spectranetics to Present at The A.G Edwards Growth Conference on September 18
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Growth Hormone Boost May Not Slow Alzheimer's
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... Boston, MA (PRWEB) , ... May 02, 2016 , ... ... and tips when trying to conceive. , “If you are ready to ... Dr. Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & ...
(Date:5/2/2016)... ... ... Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where he and ... Cities with the Highest Plastic Rates .” The other cities that made the list ... a survey by RealSelf and combining that data with the number of board-certified ...
(Date:5/2/2016)... Beach, FL (PRWEB) , ... May 02, 2016 , ... ... to great pain and suffering. With no cure, most patients must deal with prescription ... a free coupon card, allowing up to 75% savings at the pharmacy on many ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... which includes amniotic fluid/“stem cells” and Platelet Rich Plasma (PRP) injections. “These are ... said Dr. James Baranski, D.C., of Advanced Spine & Sport Medical. “We are ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
Breaking Medicine Technology: